Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 32Terminated 14Active not recruiting 8Unknown 7Recruiting 5Withdrawn 3Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 32Rituximab 24zanubrutinib 19Vincristine 16fludarabine 14Prednisone 14Magnetic Resonance Spectroscopy 14venetoclax 13blinatumomab 13Specimen Handling 13Doxorubicin 13Bendamustine Hydrochloride 11obinutuzumab 10Lenalidomide 9Dexamethasone 9polatuzumab vedotin 8Methotrexate 8Biopsy 8glofitamab 7Prednisolone 7Cytarabine 7Radiotherapy 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × etoposide phosphate × Lymphoid × Clear all
NCT07227584 2025-11-12

ALL Backbone in AYAs

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting
67 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡